

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 6-K

---

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934

---

For the month of June 2022

Commission File Number: 001-40851

---

**Procaps Group, S.A.**  
(Translation of registrant's name in English)

---

9 rue de Bitbourg, L-1273  
Luxembourg  
Grand Duchy of Luxembourg  
R.C.S. Luxembourg: B253360  
Tel : +356 7995-6138  
(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

**Note:** Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**Note:** Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

---

---

**INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K**

On June 29, 2022, Procaps Group, S.A. (the “Company”) uploaded to its website a presentation with general information about the Company including, among other, information regarding the Company’s business model, synergies with the recently acquired Grupo Somar, growth strategies and leadership.

A copy of such presentation uploaded to the Company’s website is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated by reference herein.

**Exhibit Index**

<b>Exhibit Number</b>	<b>Exhibit Title</b>
99.1	<a href="#">Presentation of Procaps Group S.A., dated June 2022 – One of the Fastest Growing and Innovative Pharma Organizations in Latin America</a>

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PROCAPS GROUP, S.A.

By: /s/ Ruben Minski  
Name: Ruben Minski  
Title: Chief Executive Officer

Dated: June 29, 2022



**One of the fastest growing  
and innovative Pharma  
organizations in Latin  
America**

June, 2022

NASDAQ: PROC

## DISCLAIMER

This presentation was prepared for informational purposes only by Procaps Group, S.A., a public limited liability company (société anonyme) governed by the laws of the Grand Duchy of Luxembourg and contains financial forecasts with respect to certain financial metrics of Procaps. The independent registered public accounting firm of Procaps has not audited, reviewed, compiled, or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and accordingly, neither of them expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this presentation. The financial forecasts and projections in this presentation were prepared by the management of Procaps, and these financial forecasts and projections should not be relied upon as being necessarily indicative of future results. Procaps does not undertake any commitment to update or revise the projections, whether as a result of new information, future events, or otherwise. In this presentation, certain of the above-mentioned projected information has been repeated (in each case, with an indication that the information is an estimate and is subject to the qualifications presented herein), for purposes of providing comparisons with historical data. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic, and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Accordingly, there can be no assurance that the prospective forecasts are indicative of the future performance of Procaps or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved.

This presentation includes "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include projected financial information. Such forward-looking statements with respect to revenues, earnings, performance, strategies, synergies, prospects, and other aspects of the businesses of Procaps are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: (1) the inability to recognize the anticipated benefits of the acquisition of Al Soar (Netherlands) BV ("Somar Holding"), Química y Farmacia S.A. de C.V. ("Quifa"), PDM Acondifarma S.A. de C.V. ("PDM"), Gelcaps Exportadora de México S.A. de C.V. ("Gelcaps"), and Grupo Farmacéutico Somar S.A.P.I. de C.V. ("Somar"), and together with Somar Holding, Quifa, PDM and Gelcaps, collectively, "Grupo Somar" which may be affected by, among other things, competition, and the ability of the combined business to grow and manage growth profitably, or of any merger or acquisition contemplated by the Company; (2) the inability to successfully retain or recruit officers, key employees, or directors; (3) effects on Procaps' public securities' liquidity and trading; (4) the lack of a market for Procaps' securities; (5) Procaps' financial performance following the acquisition; (6) costs related to the acquisition; (7) changes in applicable laws or regulations; (8) the possibility that Procaps may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties indicated from time to time in documents filed or to be filed with the Securities and Exchange Commission ("SEC") by Procaps. Accordingly, forward-looking statements, including any projections or analysis, should not be viewed as factual and should not be relied upon as an accurate prediction of future results. The forward-looking statements contained in this presentation are based on our current expectations and beliefs concerning future developments and their potential effects on Procaps. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the ability to recognize the anticipated benefits of the acquisition of the Grupo Somar, the impact of COVID-19 on Procaps' business, costs related to the acquisition and integration of the Grupo Somar, changes in applicable laws or regulations, the possibility that Procaps may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, including those included under the header "Risk Factors" in Procaps' annual report on Form 20-F filed with the SEC, as well as Procaps' other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.

The financial statement information and data for Procaps contained in this presentation have been prepared in accordance with the Normas de Información Financieras ("MFRS") issued by the Consejo Mexicano de Normas de Información Financiera, A.C. MFRS differs in certain significant respects from IFRS. As a result, the financial information and data of Procaps contained in this presentation prepared under IFRS are not directly comparable to the financial information and data of Grupo Somar contained in this presentation prepared under MFRS. Procaps has not included a description of the principal differences between IFRS and MFRS in this presentation.

This presentation includes non-IFRS financial measures, including Adjusted EBITDA and EBITDA. Management believes that these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to Procaps' and Grupo Somar's financial condition and results of operations. Procaps believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends. Management does not consider these non-IFRS measures in isolation or as an alternative to financial measures determined in accordance with IFRS. Other companies may calculate non-IFRS measures differently, and therefore the non-IFRS measures of Procaps included in this presentation may not be directly comparable to similarly titled measures of other companies.

Certain amounts included herein have been expressed in U.S. dollars for convenience and, when expressed in U.S. dollars in the future, such amounts may be different from those set forth herein.

In this presentation, Procaps relies on and refers to information and statistics regarding the sectors in which Procaps competes and other industry data. Procaps obtained this information and statistics from third-party sources, including reports by market research firms. Procaps has not independently verified the accuracy or completeness of the data contained in these third-party sources and other publicly available information.

Accordingly, neither Procaps nor its affiliates and advisors make any representations as to the accuracy or completeness of these data. Procaps has supplemented this information where necessary with information from Procaps' own internal estimates, taking into account publicly available information about other industry participants and Procaps' management's best view as to information that is not publicly available. Procaps also owns or has rights to various trademarks, service marks and trade names that it uses in connection with the operation of its businesses. This presentation also contains trademarks, service marks and trade names of third parties, which are the property of their respective owners. The use or display of third parties' trademarks, service marks, trade names or products in this presentation is not intended to, and does not imply a relationship with Procaps, or an endorsement or sponsorship by or of Procaps. All rights to the trademarks, copyrights, logos and other intellectual property listed herein belong to their respective owners and Procaps' use thereof does not imply an affiliation with, or endorsement by the owners of such trademarks, copyrights, logos and other intellectual property. Solely for convenience, the trademarks, service marks and trade names referred to in this presentation may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that Procaps will not assert, to the fullest extent under applicable law, its rights or the right of the applicable licensor to these trademarks, service marks and trade names.

This presentation is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities in any jurisdiction, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act and applicable regulations in Luxembourg.

This presentation is not intended to form the basis of any investment decision by the recipient and does not constitute and should not be construed as investment advice and does not constitute investment, tax, or legal advice.



# Team Members Presenting Today



**Ruben Minski**  
Founder – Chairman –  
Chief Executive Officer



 Northeastern University  
Chemical Engineering

 HARVARD BUSINESS SCHOOL  
Owners / President Management Program

 PROCAPS  
Founder, President and Director (44 years)

**Patricio Vargas**  
Chief Financial Officer



 AIAP  
Electrical & Industrial Engineering

 LUI  
MBA

 HARVARD BUSINESS SCHOOL  
Advanced Management Program

 cmpe  
Finance Vice President & Treasurer

 agrofoods  
Chief Executive Officer

 CFR  
Chief Financial Officer

**Melissa Angelini**  
Investor Relations Director



 UP Universidad de Palermo  
International Relations

 Insper  
MBA

 Blou  
Investor Relations Officer

 GBT Grupo Biotecnia  
Investor Relations Officer

 MZ  
IR Client Executive



## AGENDA

- I. Our Business
  - II. Why Procaps
  - III. Grupo Somar
  - IV. Growth Strategy
  - V. Leadership & ESG
-





# Procaps At A Glance



Largest pharmaceutical integral CDMO in LatAm and top 5 globally in terms of softgel production capacity<sup>(1)</sup>



Integrated pharma company uniquely positioned to drive pan-regional consolidation

45+ Year-Old Company, 5,300+ collaborators with a start-up mentality



Presence in 13 countries and expansion into Mexico with the acquisition of Grupo Somar<sup>(2)</sup>



US\$ mm

Net Revenues

Adj. EBITDA<sup>(3)</sup>

2020 2021 2020 2021

331 → 410 85 → 100

164 → 184 27 → 32

Our products are sold & distributed in ~50 markets worldwide



Focus on maintaining strong history of ESG principles



In-house R&D capabilities with strong scientific expertise, supporting the expected launch of 150+ products every year



7 manufacturing facilities in Latin America including first RX FDA-approved pharmaceutical plant on the continent



6 additional plants in Mexico subject to COFECE's approval, including 3 OTC FDA-approved (2 Softgel facilities)



Vertically-integrated to provide patented oral drug delivery technology and manufacturing capabilities



Source: Procaps, QVR Research

Notes: (1) QVR Research market report as of 2020; (2) The transaction is expected to close in 4Q22, subject to the approval of the Federal Economic Competition Commission (COFECE) in Mexico; the transaction includes Química y Farmacia, Gelcaps and related entities; (3) Refer to Form 20-F for adjusted EBITDA reconciliation



# Solid Business Model with Strong Product Diversification

Multiple growth avenues through a diverse portfolio of products & services



~30% **B2B** + ~70% **B2C**



iCDMO

Prescription products (Rx)

OTC products

Diabetes solutions

- Integral Contract Development and Manufacturing Organization
- Proprietary Softgel Technology: Unigel, Versagel, Chewgel, G-tabs and specialized gummies
- Global Pharma as clients for over 18 years

- Branded Generics in 9 different therapeutic areas
- High complexity products for private institutions

- Extensive portfolio of OTC consumer healthcare products

- A pharma 4.0 solution: a patient-centric, holistic approach
- Comprehensive portfolio of innovative products and differentiated services

Net Revenue  
CAGR 2019-2021:

~11%

Analgesics



~8%

Feminine Care



~14%

Antibiotics



~21%

Vitamins



~14%

Health solutions for diabetes | BGMS





# Highly Attractive Financial Profile



## High Growth in a Resilient Market

### Net Revenues



**Q122 Net Revenues increased 11% vs. Q121**

## Profitable Portfolio of Drugs & CDMO

### Gross Profit



## Financial Discipline and Operational Leverage

### Adj. EBITDA<sup>(1)</sup>



**Q122 Adjusted EBITDA increased 15% vs. Q121**

Notes: (1) Refer to Form 20-F for adjusted EBITDA reconciliation



## What have we done since IPO?



### Delivering on M&A Growth Strategy

- Acquisition of Grupo Somar a leading pharma company in Mexico that engages in the development, manufacture, and commercialization of high-quality products
- This acquisition is aligned with Procaps's long-term strategy



### CDMO Expansion in the US

- Acquisition of an 86,600sqm production facility and pharmaceutical R&D center in West Palm Beach, Florida to expand global growth of its iCDMO business unit



### Gummy Expansion in the US

- Construction of a new gummy manufacturing facility in Florida to support increased US demand of advanced gummy technologies



### Debt Refinancing

- Reduction in financial expenses due to convenient interest rate from PPN<sup>(1)</sup>
- Change in the debt mix to mostly long term
- Improvement of liquidity financial metrics



### Management Restructuring

- Ruben Minski as Chairman and CEO
- New senior hires with Camilo Camacho as COO and Patricio Vargas as CFO
- Strengthening of the accounting team
- IT controls to reduce material weakness
- Melissa Angelini as Investor Relations Director



### ESG

- Board of Directors with independent members
- M&A & Audit Committees
- Improvement of our ESG strategy: Materiality analysis and ESG Report





## AGENDA

- I. Our Business
  - II. Why Procaps
  - III. Grupo Somar
  - IV. Growth Strategy
  - V. Leadership & ESG
-



# Why Procaps

Investment Pillars That Makes Us a Unique Investment Case






# In-House R&D Capabilities Driving Attractive Growth Opportunities

Clear avenues for growth given a robust pipeline and a high product renewal rate




-  **600+ products** developed in softgels
-  **150+ products** launched per year
-  **50+ first launch products** annually worldwide
-  **270+ skilled personnel** in R&D and innovation
-  **500+ formulations**

Renewal Rate continues to grow as R&D investments are increasing



Relevant R&D Expenditure



*Innovative delivery mechanisms allow Procaps to transform Branded Generics into differentiated products, valued by both patients and physicians*



# Strong Growth Leading to Increasing Market Share


Procaps is the **TOP 2** most preferred company in prescription across the region



Double Digit Growth YTD 2021: 31%

YTD Growth (%) November 2021

In Our 13 Markets<sup>(1)</sup>



Source: IQVIA – Close Up November 2021

Notes: (1) Consists of the 13 markets in which Procaps currently operates; market share based on product sales revenue



# Procaps Positioned to Capitalize on Favorable Regional Dynamics

## “Right Place, Right Time”




### Top Market Share Gainers

Rank (2021)	Company	Change
1 <sup>st</sup>	<b>PROCAPS</b>	<b>+29%</b>
2	<b>Bagó</b>	+21%
3	<b>MENARINI</b>	+21%
4	Tecnquímicas	+20%
5	<b>Megalabs</b>	+17%
6	<b>Siegfried</b>	+13%
7	<b>Abbott</b>	+12%
8	<b>Bayer</b>	+11%
9	<b>esk</b>	+10%
10	<b>SANOFI</b>	+9%


Procaps is one of the fastest growing companies out of the top 10 in the markets in which we operate... and we are adding **Grupo Somar** as the 2<sup>nd</sup> largest in volume in Mexico

### Pharma Sales



...LatAm's pharma sales expected to outperform global growth...

### Aging Population in LatAm



...LatAm's aging population will increase boosting demand for pharma

Source: IQVIA Institute 2021 Global Medicine Spending and Usage Trends, Outlook to 2025, 2021Fitch Pharmaceuticals & Healthcare Report 2020, BMI 2019 and UN Department of Economics and Social Affairs, IQVIA  
 Note: (1) Derived from 2022E-2025E expected CAGR of 10.3% & 2021-2022 growth of 11.6%, per IQVIA

## Regional Pharmaceutical Player with Global Reach

Presence in 13 Countries with Product Reach Across ~50 Markets



- **First FDA-approved** Rx pharma plant in South America
- **One of the only 5 Hormonal Softgel plants** in the world
- **Centralized R&D Platform** based in Colombia with advanced technology and strategic positioning
- **Cost-efficient manufacturing** facilities  
Manufacturing plants approved by **US, Canada, Australia and Europe Regulatory Agencies** for both Rx and OTC products



Certified by highly-regulated countries



Health  
Canada



TGA

Health Safety  
Regulation



Source: Procaps

Notes: (1) Subject to the approval of the Federal Economic Competition Commission (COFECE) in Mexico; (2) Includes Biokemical's manufacturing facility



# Proprietary Portfolio of Branded Rx and OTC Products


## Well Diversified Proprietary Portfolio



### Product Portfolio Diversification...

Revenue (%) – Q122

- Top 10 Selling Brands
- Others



- ✓ Clenox (5%)
- ✓ Glucoquick (3%)
- ✓ Ezolium (2%)
- ✓ Betaduo (4%)
- ✓ Gestavit (3%)
- ✓ Artribion (2%)
- ✓ Muvett (4%)
- ✓ Citragel (3%)
- ✓ Isoface (4%)
- ✓ Nutrigel (2%)

### ...With Presence in Several Therapeutics Areas

- ✓ Feminine Care
- ✓ Pain Relief
- ✓ Skin Care
- ✓ Digestive Health
- ✓ Growth & Development
- ✓ Cardiology
- ✓ Respiratory
- ✓ Vision Care
- ✓ Gastro - Intestinal
- ✓ Personal Protective Equip.
- ✓ Antibiotics
- ✓ Immuno - supressants
- ✓ Oncology
- ✓ Analgesics
- ✓ Urology
- ✓ Cough & Cold
- ✓ VMs
- ✓ CNS
- ✓ Blood Clots

**Grupo Somar<sup>(1)</sup> operates in strategic therapeutic areas and also offers a complementary product portfolio in the same segments that Procaps pursues**

Source: Procaps Q122

Notes: (1) The transaction is expected to close in 4Q22, subject to the approval of the Federal Economic Competition Commission (COFECE) in Mexico; the transaction includes Guimica y Farmacia, Gelcaps and related entities

## Leading Pharmaceutical Integral CDMO Specialized in Softgels

One of the main providers of Softgel advanced technologies for global pharmaceutical and nutraceutical companies



- **Largest** pharmaceutical Softgel
- **CDMO** in LatAm and **top 5 globally** in terms of softgel production capacity
- **5–10-year** contracts; **~70%** of which are **USD-denominated**
- **Over 639 SKUs** across **~300** product lines
- Over **126 clients** in more than **32 countries** with strong and increasing US presence

Client Base of Global and Regional Blue-Chip Companies

	% Softgel Sales <sup>(1)</sup>	Relationship (Avg. Years) <sup>(2)</sup>	Selected Clients
Big Pharma	26%	~18	
Regional Pharma	52%	~8	
Big Suppliers Players	22%	~9	

Source: Procaps

Notes: (1) As of December 2023; (2) Average relationship years is based on revenue weighted average



## AGENDA

- I. Our Business
  - II. Why Procaps
  - III. Grupo Somar**
  - IV. Growth Strategy
  - V. Leadership & ESG
-



# Procaps & Somar's Business Models Have a Strong Strategic Alignment

Well-aligned and highly complementary cultures and business models



## Core Capabilities



Proprietary portfolio of branded prescription and OTC products, focused on the private market

Direct presence in 13 countries

210+ products in Mexico



State-of-the art facilities capable of manufacturing highly complex products

7 plants +Proprietary Softgel Technology

6 plants in Mexico, with 3 FDA approved and 2 Softgel



Partner of choice to leading global pharma companies through CDMO business

~18 Years of relationship with clients

FDA approved plant with Softgel production



Strong R&D capabilities and focus on innovation translating into robust pipeline of new products

R&D centers in Latin America and the US

R&D center in Mex, with room to increase capacity



Highly experienced, specialized salesforce

440+ sales force in Latin America

Sales force in Mexico for RX, BGx and OTC



Experienced and proven Management Team

Latam experienced team, innovation culture

Team with Mexican knowledge



## Procaps & Grupo Somar Merger Provides Attractive Synergies

The acquisition of Grupo Somar is expected to deliver relevant synergies for Procaps



### Anticipated OpEx Efficiencies

- Corporate **back-office optimization** is expected to result in **expense reduction**
- **Standardization** of technological platforms and administrative processes **optimization of manufacturing facilities (redundancies)**

### R&D Efficiencies

- Implementation of best practices and know-how in the development of products is expected to **increase the current capacity of launches**



### Anticipated COGS Efficiencies

- **Strategic alliances with suppliers** to become key regional customer
- Exports packaging concentration **in a free trade zone to optimize costs**
- **Specialization and concentration in Mexico** of solids, semi-solids and liquids for the region

### Cross-Selling Opportunities

- More than 30 **products of Grupo Somar's** existing and developing portfolio are expected to be **launched in the regions Procaps operates** in between 2023 and 2025
- Products of **Procaps'** existing and developing portfolio are expected to be **launched in Mexico via Grupo Somar**



## AGENDA

- I. Our Business
  - II. Why Procaps
  - III. Grupo Somar
  - IV. Growth Strategy**
  - V. Leadership & ESG
-





# Agile Business Model To Identify Growth And Time-to-Market

Our 5 main growth pillars



Our Strategy

1

Innovative Technology & Health Solutions

2

Geo Expansion

3

Robust and relevant portfolio

4

Operational Excellence

5

Accretive M&As



Growth Avenues

Innovative delivery mechanisms to transform BGx into differentiated products, with high value added, Health Solutions

Leverage on Colombia's portfolio in LatAm and Mexico cross sell opportunities

New Therapeutic Areas and Products with focus on high complexity drugs, chronic diseases, specialty products, new Geographies

Industry and capacity expansion both for CDMO and proprietary drugs

Sustainable growth towards global expansion

*Recurring investments in R&D, innovation and optimization*



## Innovative Technology & Health Solutions

Continuous investments in proprietary technology & health solutions to accelerate Procaps growth path

### Proprietary Technology

**g-Tabs**  
Gelatin, coated tablets, easy to swallow and impossible to counterfeit

**funxtrition**  
Delivering easy nutrition with a variety of formulations in nutritional gummies

**Chew gels**  
Chewable soft capsules technology is a new solution for children and consumers who have difficulty swallowing

**SoftGels**  
Consumers' preferred dosage form

**unigel**  
The Smart Softgel for multi-dose therapies, multi-purpose products

**Versa gel**  
Versatile plant based softgel (Big seller in USA, Europe and Middle East)



### Holistic Health Solutions

**Digital Health Platform** that helps patients/doctors/insurers to manage chronic diseases

Promoting **personalized and preventive care**, leveraged on telehealth and homecare which enables adherence to medical treatment

**Already operational for Diabetics** and upcoming migration to other chronic diseases

### Disruption of the business model

**Launch of e-shop platform**, services at demand, premium services subscription

**Direct medical prescriptions** to e-pharmacy for home delivery

**Direct-to-consumer** business model with seamless digital experience in the patient journey



# Geo Expansion of Existing Portfolio

Clear strategy to propel strong organic growth in a diversified portfolio




## New Registrations by Country




**Mexico expected cross selling opportunities: 210+ products**

## Size of Pharmaceutical Market in LatAm Markets by Major Country



## Evolution of New Registrations in LatAm Countries



Source: Size of pharmaceutical markets IQVIA + Knobloch Mexico, MAT Dic 2021; Central America includes Guatemala, Costa Rica, Honduras, Panama, El Salvador, Nicaragua. New registrations in the last 36 months in each country.



# Agile Business Model To Identify Growth And Time-to-Market

## Robust and relevant portfolio



### Top Global Sales by Product Line

Ranking	Product Line	Global Sales 2024E (USD bn)	Pipeline + Somar
1	Oncology	223	✓
2	Anti-diabetes	51	✓
3	Anti-rheumatic	57	✓
4	Vaccines	45	✓
5	Anti-viral	40	✓
6	Immunosuppressants	38	✓
7	Bronchodilators	32	✓
8	Dermatological	30	✓
9	Sensory Organs	27	✓
10	Anti-hypertensive	24	✓


Source: The Cancer Atlas – The Burden, Regional Diversity – Latin America and the Caribbean

### Most Common Types of Cancer in LatAm in Procaps' pipeline

Cancer incidence rate by type (%) (in Pipeline)

14%	Prostate	✓	15%	Breast	✓
9%	Colon and Rectum	✓	9%	Colon and Rectum	✓
9%	Trachea, Bronchus and Lung	✓	9%	Trachea, Bronchus and Lung	✓
5%	Stomach	✓	5%	Stomach	✓
4%	Skin	✓	4%	Skin	✓

### Robust Pipeline in Development





## Operational Excellence


State-of-the-art manufacturing capabilities providing innovative delivery technologies



### Industrial Complex Expansion Roadmap

2022

2023



■ Colombia ■ Brazil ■ El Salvador ■ United States ■ Mexico

Source: Procaps, Grupo Somar

Note: (1) The transaction is expected to close in 4Q22, subject to the approval of the Federal Economic Competition Commission (COFECE) in Mexico; the transaction includes Química y Farmacia, Gelcaps and related entities

### Highlights

- Procaps operates **state-of-the-art manufacturing facilities and development centers** in LatAm
- **First plant to receive FDA approval in Latin America** (Procaps Barranquilla)
- Multiple projects related to **plant improvements, capacity expansion and new equipment and technology** in recent years
- Grupo Somar<sup>(1)</sup> has **strong manufacturing capabilities that we believe can support sustainable growth**



## Inorganic Growth: M&A

Established Platform with M&A turnaround capabilities ready to continue inorganic growth



### Integration Plan | Grupo Somar



Initial Integration Plan with actions to target main business areas of Somar **for the next 12 – 18 months.**

Our internally developed post M&A strategy is used in order to **produce tangible results**, such as:

- Capture **short term synergies**
- **Accelerated growth** and **culture** integration
- Consolidate corporate **management team** and **talent retention**
- Eliminate duplications, which leads to **significant savings**
- Strong **internal control** and **centralized finance** area
- Register **Mexico's products** in LatAm
- Register **Colombia's products** in Mexico
- Increase or gain **global pharma contracts** for CDMO services
- **Accelerate R&D** pipeline and development



### What's Next for M&A



Procaps is constantly looking for M&A opportunities in target countries if they fit certain conditions:

- Added value drugs on their portfolio
- Operate in strategic therapeutic areas
- Complementary portfolio in the same segment or segment we want to pursue
- Strategic fit with Procaps

### Geographical Focus



Potential geographical focus:

- Underpenetrated markets, potential targets for consolidation
- **Pharma targets** in Latin America
- **CDMO targets** in Brazil and the US



## Where Do We Want to Be in ~5 Years

Well positioned for future growth with earlier anticipated results



-  **Regional B2C leader** in South and Central America
-  **Global Player** in the B2B segment
-  **Proprietary portfolio** of branded RX and OTC products
-  **Mid-teens Annual** organic growth rate

### Growth Driven By:

-  **New product launches** and continued **rollout of our existing portfolio** in new countries, across every SBU
-  **Demand achieved through our Rx and OTC brands**
-  **Higher growth** of CDMO services

### Net Revenue



### Adjusted EBITDA





## AGENDA


- I. Our Business
  - II. Why Procaps
  - III. Grupo Somar
  - IV. Growth Strategy
  - V. Leadership & ESG
-





# Founder-Led and Strong Governance

## Seasoned Management Team and Complete Corporate Governance Structure





# Improving Standards of Environmental, Social and Governance Initiatives

Well positioned to capitalize on future growth opportunities



## Environmental

- Green culture committed to environmental best practice to meet or exceed environmental regulations
- Production policies focused on rational use of raw material and less packaging materials
- Process optimization in all plants while better managing waste and protecting energy and water resources



## Social

- Management and execution of sustainable projects and programs that contribute to social development in the Caribbean region
  - 126,000+ Children and teenagers
  - 3,740+ Expectant mothers
  - 5,500+ Elderly population
  - 179,000+ Health Days
  - 2,300+ volunteers
- Expanding the availability and access of our portfolio of effective, safe and quality products and innovative technologies in the region



## Governance

- Corporate governance that leads efforts towards strategic objectives, monitoring integrity, transparency and internal processes carried out by the Corporation
- Implementation of committees (Audit; Strategy and M&A; HR, Compensation and Governance)



**Thank you**

[ir@procapsgroup.com](mailto:ir@procapsgroup.com)  
[Investor.procapsgroup.com](http://Investor.procapsgroup.com)

NASDAQ: PROC